Kaleo, Inc.

Other

Insmed Incorporated

Glen L Kelley

Eric S Edwards

Evan Thomas Edwards

Paul F Meyers

Frank E Blondino

Mark C Sleevi

A method of delivering epinephrine includes placing a distal end surface of a medical injector into contact with a target location of a patient. The medical injector includes a housing, an energy storage member, and a medicament container containing a dose of epinephrine effective for administration to the patient experiencing anaphylaxis and having a weight of less than 15 kg. The medicament container is coupled to a needle. The medical injector is actuated such that the energy storage member produces a force to move the needle from a first needle position to a second needle position. A distal tip of the needle extends from the distal end surface by a distance of between 7 millimeters and 8 millimeters when the needle is in the second needle position. A portion of the force is exerted to expel the dose of epinephrine when the needle is in the second position.

Medicament delivery device and methods for delivering drugs to infants and children

An apparatus includes a container, a needle, and an actuation assembly. The container contains a dose of a naloxone composition having a delivered volume of at least about 0.34 mL. The actuation assembly includes an energy storage member that produces a force on a movable member to move the needle and to deliver the dose of the naloxone composition. The 90% confidence interval of at least one of the relative mean maximum naloxone plasma concentration after dose delivery into the body (C), time to reach the maximum naloxone plasma concentration (T), area under the plasma concentration-time curve from pre-dose (time 0) extrapolated to infinity (AUC), or area under the plasma concentration-time curve from pre-dose (time 0) to the time of the last quantifiable concentration (T) (AUC) of the delivered dose to a delivered dose of a corresponding naloxone composition delivered via a manually-actuated syringe is within 80% to 125%.

Devices and methods for delivering opioid antagonists including formulations for naloxone

Tie stay clips are disclosed. Methods of making and using tie stay clips are also disclosed.

Tie stay clips and methods of making and using the same

Complexes of IGF-I and IGFBP-3 with new levels of purity are provided. Chromatographic techniques have been developed that remove contaminants, such as mass and charge variants of IGFBP-3. The new techniques enable the production of high-quality pharmaceutical compositions comprising IGF-I/IGFBP-3 complexes.

Growing community of inventors

Glen Allen, VA, United States of America

Glen L Kelley